Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 290,876 shares at $50.51 ($15.1M) on 2022-02-11, disclosed to the SEC on 2022-02-14.
Open-market sale of $15.1M ARWR by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.51 | 1,900 | $96K | 0.6% |
| 2 | $50.90 | 61,482 | $3.1M | 20.7% |
| 3 | $50.90 | 61,482 | $3.1M | 20.7% |
| 4 | $52.28 | 42,153 | $2.2M | 14.6% |
| 5 | $52.28 | 42,153 | $2.2M | 14.6% |
| 6 | $53.11 | 40,853 |
| $2.2M |
| 14.4% |
| 7 | $53.11 | 40,853 | $2.2M | 14.4% |
| Total | $51.92 avg | 290,876 | $15.1M | 100% |
| Filing → |
| ARWR | SELL | 2025-12-23 | $3.5M | — | Filing → |
| ARWR | SELL | 2025-12-19 | $10.9M | — | Filing → |
| ARWR | SELL | 2025-12-16 | $24.6M | — | Filing → |